Discussion paper on pan-tumour biomarker testing to determine eligibility for targeted treatment.
Morona, J, Wyndham, A, Scott, P, Mitchell, A, Merlin, T
Record ID 32018000644
Authors' objectives: To provide guidance on the evidence needed to evaluate immunohistochemistry (IHC) testing for mismatch repair deficiency (dMMR) in colorectal cancer (CRC) and many other types of tumour (pan-tumour or tumour agnostic), in order to access pembrolizumab treatment. Subsequent co-dependent technology submissions seeking subsidy for biomarker testing for treatments that have pan-tumour effects may also be assessed according to this guidance.
Project Status: Completed
Year Published: 2020
URL for published report: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwiVpu65ueLqAhV7yzgGHfNmCQMQFjAAegQIARAB&url=http%3A%2F%2Fwww.msac.gov.au%2Finternet%2Fmsac%2Fpublishing.nsf%2FContent%2F9C7DCF1C2DD56CBECA25801000123C32%2F%24File%2FDiscussion%2520paper%25202020-01-13.pdf&usg=AOvVaw0QiUe5jdJFR83ykE9nnGap
English language abstract: An English language summary is available
Publication Type: Other
- Biomarkers, Tumor
- tumour agnostic
- colorectal cancer
Organisation Name: Adelaide Health Technology Assessment
Contact Address: School of Public Health, Mail Drop 545, University of Adelaide, Adelaide SA 5005, AUSTRALIA, Tel: +61 8 8313 4617
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: Adelaide Health Technology Assessment (AHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.